Related Experiment Video

Updated: Jul 19, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Antiplatelet and anticoagulant therapy in patients with giant cell arteritis

Michael S Lee1, Scott D Smith, Anat Galor

  • 1University of Minnesota, Minneapolis, USA. leex2679@umn.edu

Arthritis and Rheumatism
|September 30, 2006
PubMed

Insights

Antiplatelet or anticoagulant therapy significantly reduced ischemic events in giant cell arteritis (GCA) patients. This study found no increased bleeding risk, suggesting these therapies may be beneficial for GCA patients.

Area of Science:

  • Rheumatology
  • Neurology
  • Vascular Medicine

Background:

  • Giant cell arteritis (GCA) is associated with significant risks of vision loss and cerebrovascular accidents.
  • Antiplatelet and anticoagulant therapies are established stroke prevention methods in other patient populations.
  • The efficacy of these therapies in mitigating ischemic complications specifically within GCA patients remains an area of investigation.

Purpose of the Study:

  • To investigate the potential benefit of antiplatelet or anticoagulant therapy in reducing ischemic complications in patients diagnosed with giant cell arteritis.
  • To assess whether the use of antiplatelet or anticoagulant agents impacts the incidence of vision loss or stroke in GCA patients.

Main Methods:

  • Retrospective chart review of 143 patients meeting the 1990 American College of Rheumatology criteria for GCA.
  • Data collection included demographic information, duration of antiplatelet/anticoagulant use, and occurrence of ischemic events (vision loss, stroke).
  • Analysis compared ischemic event rates between patients receiving and not receiving antiplatelet or anticoagulant therapy, while also noting bleeding complications and cerebrovascular risk factors.

Main Results:

  • Patients receiving antiplatelet or anticoagulant therapy experienced significantly fewer ischemic events (16.2%) compared to those not on therapy (48.0%) (P < 0.0005).
  • The study included 143 patients (mean age 71.8 years, 76% female) with a mean follow-up of 4 years.
  • No statistically significant increase in bleeding complications was observed in patients undergoing antiplatelet or anticoagulant therapy.

Conclusions:

  • Antiplatelet or anticoagulant therapy appears to reduce the risk of ischemic events in patients with giant cell arteritis.
  • The use of these therapies in GCA patients did not result in a higher incidence of bleeding complications.
  • These findings suggest a potential role for antiplatelet and anticoagulant agents in the management of GCA to prevent ischemic complications.
Abstract

More Related Videos

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...